Botanix presents at Investor Seminar

- Botanix presents at the Shaw and Partners Investor Seminar
- Botanix showcased the BTX1503 acne program and initiation of first clinical trial within coming weeks

**Sydney 4 May March 2017:** Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) is pleased to release a new presentation, which Botanix Executive Director, Matt Callahan, presented at the Shaw and Partners Investor Seminar last evening.

The presentation at the seminar was used to provide an update on the Company’s lead clinical development program, involving the use of synthetic cannabidiol for the treatment of acne. Botanix was also able to showcase its rapid operational progress towards first clinical studies, which are expected to commence in the coming weeks. Completion of this first study will be closely followed by an Australian pilot study in acne patients.

**About Botanix Pharmaceuticals**

Botanix Pharmaceuticals is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which has a well-established safety profile. Botanix is preparing for the first human trials with synthetic cannabidiol utilising a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy in 1H 2017 and plans to progress the development of its pipeline of other Permetrex enabled products alone, or in collaboration with partners.

For more information on Botanix, please visit [www.botanixpharma.com](http://www.botanixpharma.com) or follow us on Twitter @Botanixpharma.

**For more information, please contact:**

**General enquiries**
Matt Callahan  
Botanix Pharmaceuticals Ltd  
Executive Director  
P: +1 215 767 4184  
E: mcallahan@botanixpharma.com

**Investor Relations**
Ben Walsh  
WE Buchan  
P: (02) 9237 2801  
E: bwalsh@buchanwe.com.au
Media enquiries
Arthur Chan
WE Buchan
P: (02) 9237 2805
E: achan@buchanwe.com.au
Botanix is one of the most compelling emerging companies on the ASX

**Dermatology Focused**
- Multi-billion dollar market with no new products approved in last 20 years (for acne)
- Faster development pathway for dermatology products, drives lower costs and much quicker timeline to approval

**Novel Approach**
- Lead products based on synthetic form of cannabidiol - greatly enhances the probability of clinical and regulatory success
- Exclusive global rights to use Permetrex™ delivery technology for all skin diseases with potential to deliver near term revenues

**Experienced Team**
- Predominantly US based leadership team with 20+ FDA approvals between them
- Have advanced lead product from formulation to clinical trials in 9 months, and also created 5 new products using Permetrex™ delivery technology
Corporate overview

Innovative medical dermatology company with a clear path to commercialisation

Trading information

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Share price (2-May-17)</td>
<td>A$0.05</td>
</tr>
<tr>
<td>52 week low / high</td>
<td>A$0.026 / A$0.075</td>
</tr>
<tr>
<td>Shares on issue¹²</td>
<td>506.7m</td>
</tr>
<tr>
<td>Market capitalisation</td>
<td>A$25.3m</td>
</tr>
<tr>
<td>Cash (as at 31-Mar-17)³</td>
<td>A$6.9m</td>
</tr>
<tr>
<td>Debt (as at 31-Mar-17)</td>
<td>Nil</td>
</tr>
<tr>
<td>Enterprise value</td>
<td>A$18.4m</td>
</tr>
</tbody>
</table>

Share price performance

Share price (A$)

Volume (m)

Top shareholders (as at May 2017)

<table>
<thead>
<tr>
<th>Shareholder</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Callahan – Executive Director</td>
<td>13.9</td>
</tr>
<tr>
<td>Caperi Pty Ltd – Co-founder</td>
<td>13.9</td>
</tr>
<tr>
<td>Board and management (excl. shareholders above)</td>
<td>4.0</td>
</tr>
</tbody>
</table>

Source: IRESS

¹. Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018
². Excludes 39.3m unlisted options with exercise price range of A$0.03 - A$0.0675 and expiry date range of Jan 2018 to Jan 2020
³. Cash balance adjusted for Tranche 1 of placement announcement in April 2017
Senior leadership: track record of success

Proven industry professionals with experience in rapid development of pharmaceuticals

Mr Matthew Callahan
Executive Director
- Developed 3 products to date that have received FDA approval, 1 pending approval
- Previous investment director of 2 venture capital firms investing in life sciences

Dr Bill Bosch
Executive Director
- 6 FDA approved products and inventor of the iCeutica SoluMatrix Technology
- Founder of NanoSystems and co-inventor of drug delivery technology NanoCrystal

Dr Michael Thurn
Chief Operating Officer
- Extensive start up life sciences experience across a range of technology platforms
- Previous MD of Spinifex Pharmaceutical, which sold to Novartis for A$700m

Dr Mark Davis
VP Clinical and regulatory
- 30 years clinical experience with 19 FDA approved products across dermatology
- Former clinical lead with Medicis and Connetics and FDA experience with cannabidiol

20+ FDA approved products credited to the broader Botanix leadership team
Botanix’s market positioning

- Farming
- Whole plant or extract
- Health, Cosmetics, Veterinary
- Long development cycle
- Making products
- Single chemical
- Regulated pharmaceuticals
- Fast path to market
Botanix’s acne product – BTX 1503

Topically applied gel for the treatment of moderate and severe acne

- Stops excessive oil or ‘sebum’ production
- Reduces inflammation
- Blocks cell proliferation
- Attacks bacteria

BTX 1503 targeting a benign side effect profile

Key advantage 1 – synthetic material

Use of synthetic cannabidiol greatly increases the chance of clinical success and regulatory approval, at a much lower COGS than naturally extracted material.

<table>
<thead>
<tr>
<th>Synthetic cannabidiol</th>
<th>Naturally extracted cannabidiol</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 chemical</td>
<td>100+ chemicals</td>
</tr>
<tr>
<td>100% pure</td>
<td>Multiple impurities (anything above 0.05% needs to be identified and tested)</td>
</tr>
<tr>
<td>Scaled up to 50kg</td>
<td>Scaled up to &lt;1kg</td>
</tr>
<tr>
<td>No additional compliance required</td>
<td>Must comply with FDA’s “Botanical Drug Development Guidance for Industry”</td>
</tr>
</tbody>
</table>

Only synthetic cannabidiol drug material has been registered with FDA – no botanical extracts.

Key advantage 2 – drug delivery

Permetrex™ technology drives synthetic cannabidiol directly into the skin – oral administration only delivers ~6% to the blood, most of which does not get to skin organs.

Botanix holds the exclusive rights to utilise Permetrex™ for all drugs that treat skin diseases.
**Significant and growing market opportunity**

Global market for acne prescription products market expected to grow to >US$4.5bn and is only a subset of the global dermatology opportunity.

**Value of the global acne prescription market is expected to reach US$4.5bn by 2018**

<table>
<thead>
<tr>
<th>Year</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>US$3,845m</td>
</tr>
<tr>
<td>2013</td>
<td>US$3,951m</td>
</tr>
<tr>
<td>2018</td>
<td>US$4,530m</td>
</tr>
</tbody>
</table>

**Top branded acne products containing only generic drugs have achieved revenues of up to >US$300m p.a.**

<table>
<thead>
<tr>
<th>Brand</th>
<th>Year 2011</th>
<th>Year 2012</th>
<th>Year 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epiduo (Galderma)</td>
<td>US$331m</td>
<td>US$285m</td>
<td>US$285m</td>
</tr>
<tr>
<td>Aczone (Allergan)</td>
<td>US$199m</td>
<td>US$175m</td>
<td>US$168m</td>
</tr>
<tr>
<td>Tazorac (Allergan)</td>
<td>US$168m</td>
<td>US$167m</td>
<td>US$167m</td>
</tr>
<tr>
<td>Differin (Galderma)</td>
<td>US$95m</td>
<td>US$85m</td>
<td>US$85m</td>
</tr>
</tbody>
</table>

- No new chemical entities approved by the FDA in the last 20 years for the treatment of acne
- Only “new” products in this period were combinations of old drugs in new formulations
- Little development underway, with very few products currently in the development pipeline

---

1. BCC Research, May 2013. Skin Disease Treatment and Global Markets
2. Symphony Health Solutions, Pharmaceutical Audit Suite for 2012 as reported in Demira S1
Recent dermatology transactions

Licensing and partnering transactions are potential monetisation options

Dermatology transactions

<table>
<thead>
<tr>
<th>Deal date</th>
<th>Licensee/Acquirer</th>
<th>Licensor/Target</th>
<th>Deal type</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sep 15</td>
<td>Allergan (rights)</td>
<td>AstraZeneca</td>
<td>License</td>
<td>In Phase III</td>
</tr>
<tr>
<td>Dec 2016</td>
<td>sienna pharma</td>
<td>anterios</td>
<td>Corporate</td>
<td>Completed Phase I</td>
</tr>
<tr>
<td>Jan 2016</td>
<td>Allergan</td>
<td>exicure</td>
<td>Corporate</td>
<td>In pre-clinical development</td>
</tr>
<tr>
<td>Dec 2016</td>
<td>Allergan</td>
<td>Creatin</td>
<td>Corporate</td>
<td>In pre-clinical development / Phase IIb</td>
</tr>
<tr>
<td>Oct 2016</td>
<td>LEO</td>
<td>Vitae</td>
<td>Corporate</td>
<td>In Phase II</td>
</tr>
<tr>
<td>Apr 2016</td>
<td>Astellas</td>
<td>ANACOR</td>
<td>Asset/biz</td>
<td>On market</td>
</tr>
<tr>
<td>May 2016</td>
<td>pfizer</td>
<td></td>
<td>Corporate</td>
<td>Completing Phase III</td>
</tr>
</tbody>
</table>

Total upfront and milestone payments could exceed these figures in aggregate

Source: Bloomberg, Company disclosure

For personal use only
Primary strategy is commercialising BTX 1503, with a supportive pipeline of other medical dermatology products and opportunities for near term revenue generation.

**Near term focus**
- **BTX 1503 development and commercialisation**
  - Accelerating clinical development through undertaking low cost clinical studies in Australia, feeding into a US FDA approval

**Near to medium term focus**
- **Permetrex™ licensing**
  - Licensing Permetrex™ delivery system to strategic parties, to generate potential near term revenue

**Medium to long term focus**
- **Other pipeline products**
  - Leverage data from BTX 1503 program to accelerate development of new products in psoriasis and dermatitis and other products that do not require FDA approval
Botanix key catalysts

Significant operational milestones expected over the next 9 months, as Botanix launches first human studies and accelerates corporate development

Indicative activities and milestones

- Phase Ia safety, dosing and pharmacokinetic trial
- Phase Ib acne patient pilot study
- FDA approval for Phase II trial
- Phase II multi-centre acne patient study
- Pilot study BTX 1701 (cleanser)
- Patient study BTX 1701
- Study BTX 1204 (dermatitis)

Clinical milestones where potential licensing deals may be considered
Disclaimer

This presentation prepared by Botanix Pharmaceuticals Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.